Trial Profile
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone in Adults =65 Years of Age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2014
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 25 Aug 2009 Actual patient number changed from 3837 to 3876 as reported by ClinicalTrials.gov.
- 15 Jul 2009 Results published in the Journal of Infectious Diseases.
- 26 Oct 2008 Results have been reported at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting, according to a Sanofi Pasteur media release.